RETRACTED ARTICLE: Association between APE1 T1349G polymorphism and prostate cancer risk: evidence from a meta-analysis

APE1 T1349G polymorphism was considered to be associated with risk of cancer, but studies on the association between APE1 T1349G polymorphism and risk of prostate cancer remained inconclusive. A meta-analysis of published studies was performed to precisely assess the association between APE1 Asp148Glu polymorphism and prostate cancer risk. PubMed, Embase, and Wanfang databases were searched for published case–control studies investigating the association between APE1 T1349G polymorphism and prostate cancer risk. Odds ratios (ORs) and 95 % confidence intervals (95 % CIs) were used to assess the strength of the association. Overall, seven studies with a total of 3,063 individuals were finally included into the meta-analysis. The heterogeneity analysis did not find obvious heterogeneity among those included studies. Meta-analysis of total seven studies did not find an obvious association between APE1 T1349G polymorphism and prostate cancer risk (G vs T OR (95 % CI) = 1.11 (0.99–1.24); GG vs TT OR (95 % CI) = 1.25 (0.96–1.62); TG vs TT OR (95 % CI) = 1.11 (0.95–1.30); GG/TG vs T OR (95 % CI) = 1.13 (0.97–1.32); GG vs TT/TG OR (95 % CI) = 1.16 (0.91–1.48)). Subgroup analyses by ethnicity showed that APE1 T1349G polymorphism was associated with increased risk of prostate cancer in Caucasians (G vs T OR (95 % CI) = 1.26 (1.02–1.56), P = 0.033; TG vs TT OR (95 % CI) = 1.44 (1.06–1.94), P = 0.019; GG/TG vs T OR (95 % CI) = 1.45 (1.08–1.94), P = 0.013). The meta-analysis suggests that APE1 T1349G polymorphism is associated with increased risk of prostate cancer, especially in Caucasians. More studies are needed to further identify the obvious association above.